Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 69-74

  Zhang, Xiao Hua ^a   Qiao, En Qi ^b   Gao, Zhenzhen ^a   Yuan, Hua Qing ^a   Cai, Pei Fen ^a   Li, Xiao Min ^c   Gu, Yan Hong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c First People's Hospital of Lianyungang   (China)

Author keywords

Axitinib; Dacarbazine; Melanoma

Indexed keywords

AXITINIB; DACARBAZINE; GELATINASE B; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENTERITIS; FEMALE; MELANOMA; MOUSE; NICK END LABELING; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR NECROSIS; TUMOR VOLUME;

EID: 84878299289     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1345     Document Type: Article

References (24)

1. Garbe C and Leiter U: Melanoma epidemiology and trends. Clin Dermatol 27: 3-9, 2009.
2. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634, 2001.
3. Agarwala SS: Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587-595, 2009.
4. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24: 4738-4745, 2006.
5. Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939, 2011.
6. Rixe O, Bukowski RM, Michaelson MD, et al: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8: 975-984, 2007.
7. Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26: 4708-4713, 2008.
8. Schiller JH, Larson T, Ou SH, et al: Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27: 3836-3841, 2009.
9. Hersey P, Bastholt L, Chiarion-Sileni V, et al: Small molecules and targeted therapies in distant metastatic disease. Ann Oncol 20 (Suppl 6): vi35-vi40, 2009.
10. Hu-Lowe DD, Zou HY, Grazzini ML, et al: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14: 7272-7283, 2008.
11. Fruehauf J, Lutzky J, McDermott D, et al: Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 17: 7462-7469, 2011.
12. Emmett MS, Dewing D and Pritchard-Jones RO: Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res 1: 852-868, 2011.
13. Ma J and Waxman DJ: Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 15: 578-588, 2009.
14. Ma J and Waxman DJ: Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 7: 79-89, 2008.
15. Richardson G, Dobish R: Chemotherapy induced diarrhea. J Oncol Pharm Pract 13: 181-198, 2007.
16. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
17. Wilmes LJ, Pallavicini MG, Fleming LM, et al: AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25: 319-327, 2007.
18. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD and McDonald DM: Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 66: 1434-1445, 2006.
19. Spano JP, Chodkiewicz C, Maurel J, et al: Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371: 2101-2108, 2008.
20. Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12: 256-262, 2011.
21. Rugo HS, Stopeck AT, Joy AA, et al: Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 29: 2459-2465, 2011.
22. Bendell JC, Tournigand C, Bednarczyk M, et al: Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 29 (suppl 4; abstr 478): 2011.
23. Hiratsuka S, Nakamura K, Iwai S, et al: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289-300, 2002.
24. Shafi MA and Bresalier RS. The gastrointestinal complications of oncologic therapy. Gastroenterol Clin North Am 39: 629-647, 2010.